Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
15.76
-0.63 (-3.84%)
At close: Nov 18, 2026, 4:00 PM EST
16.00
+0.24 (1.52%)
Pre-market: Nov 19, 2026, 7:38 AM EST
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Arcus Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $40.92. The average 1-year stock price forecast is 159.64% higher than the current stock price, while the lowest is $23 (+45.94%) and the highest is $50 (+217.26%).
Price Target: $40.92 (+159.64%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcus Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 11 | 12 | 12 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Hold Reiterates $29 → $28 | Hold | Reiterates | $29 → $28 | +77.66% | Nov 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $41 → $40 | Buy | Reiterates | $41 → $40 | +153.81% | Nov 9, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $23 | Hold | Reiterates | $23 | +45.94% | Nov 6, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Maintains $46 → $49 | Buy | Maintains | $46 → $49 | +210.91% | Nov 5, 2026 |
| Wedbush | Wedbush | Buy Reiterates $49 → $45 | Buy | Reiterates | $49 → $45 | +185.53% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
72.34M
from 247.00M
Decreased by -70.71%
Revenue Next Year
55.78M
from 72.34M
Decreased by -22.89%
EPS This Year
-3.48
from -3.29
EPS Next Year
-3.09
from -3.48
EPS and Forward PE are based on non-GAAP adjusted numbers.